Pregnancy and breastfeeding in patients with Crohn's disease

Détails

ID Serval
serval:BIB_3A1A2654D5CE
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Pregnancy and breastfeeding in patients with Crohn's disease
Périodique
Digestion
Auteur⸱e⸱s
Mottet Christian, Juillerat Pascal, Pittet Valérie, Gonvers Jean-Jacques, Froehlich Florian, Vader John-Paul, Michetti Pierre, Felley Christian
ISSN
0012-2823
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
76
Numéro
2
Pages
149-160
Langue
anglais
Résumé
Crohn's disease commonly affects women of childbearing age. Available data on Crohn's disease and pregnancy show that women with Crohn's disease can expect to conceive successfully, carry to term and deliver a healthy baby. Control of disease activity before conception and during pregnancy is critical, to optimize both maternal and fetal health. Generally speaking, pharmacological therapy for Crohn's disease during pregnancy is similar to pharmacological therapy for nonpregnant patients. Patients maintained in remission by way of pharmacological therapy should continue it throughout their pregnancy. Sulfasalazine, mesalazine and corticosteroids are safe, azathioprine and 6-mercaptopurine are reasonably safe with few discordant data, infliximab seems safe as well, whereas methotrexate is contraindicated during pregnancy. During breastfeeding, mesalazine and prednisone are considered safe, azathioprine/6-mercaptopurine, budesonide and infliximab probably safe and methotrexate is contraindicated. [Ed.]
Mots-clé
Anti-Infective Agents, Anti-Infective Agents/therapeutic use, Anti-Inflammatory Agents, Non-Steroidal, Anti-Inflammatory Agents, Non-Steroidal/therapeutic use, Breast Feeding, Crohn Disease, Crohn Disease/drug therapy, Drug Therapy, Combination, Female, Glucocorticoids, Glucocorticoids/therapeutic use, Humans, Immunologic Factors/therapeutic use, Mesalamine, Pregnancy, Pregnancy Complications, Pregnancy Complications/drug therapy, Pregnancy Outcome, Safety
Pubmed
Web of science
Création de la notice
03/03/2008 10:52
Dernière modification de la notice
20/08/2019 13:29
Données d'usage